The only malignancy screening test among gynecological cancers is cervical cancer. Cytology examination and Hpv typing with smear are used as screening tests. Hpv positivity is detected in more than 90% of cervical cancers. However, only the Hpv 16-18 type positive patients undergo colposcopy in the routine screening program. Patients with Smear negative, Type 16-18 high-risk Hpv positivity are evaluated by quota after 1 year. the authors performed colposcopy with this study; authors aimed to compare the results of patients with type 16-18 Hpv positivity and type 16-18 high-risk Hpv positivity and to find out whether there was any difference between them. In this way, other high-risk Hpv types other than type 16-18 (31,33,35,45,51, etc.) may be exposed to premalign cervical lesions and possible cancer in a number of earlier and earlier periods by performing colposcopic examination instead of expecting to perform quota after 1 year. we aimed to remove.
Study Type
OBSERVATIONAL
Enrollment
409
high-risk hpv positivity and colposcopy and cervical biopsy results will be evaluated. thus, it will be defined whether colposcopy will be performed routinely at high-risk hpv.
Kanuni Sultan Süleyman Training and Research Hospital
Istanbul, Turkey (Türkiye)
Genotype of HR-HPV 16/18
Results of colposcopies and retrieved colposcopic biopsy of patients with Genotype of HR-HPV 16/18
Time frame: 1 MONTH
Genotype of HR-HPV non 16/18
Results of colposcopies and retrieved colposcopic biopsy of patients with Genotype of HR-HPV non 16/18
Time frame: 1 MONTH
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.